Novartis Vaccines produces some of the world's most widely used vaccines against diseases of particular concern to travelers or to people living in highly endemic risk areas, e.g. rabies and Tick-borne Encephalitis.

Encepur® Children
A formulation uniquely developed for children (from 1-11 years of age)

Encepur® Adults
A formulation especially designed for adolescents and adults (from 12 years of age)

Encepur® Children/ Encepur® Adults has proven to be highly effective in protecting against tick-borne encephalitis (TBE). Also known as spring-summer encephalitis, TBE is a viral infection of the central nervous system transmitted by bites of certain kinds of infected ticks. The disease is found in countries throughout Europe and Asia and causes flu-like symptoms and can also cause illnesses such as meningitis and meningoencephalitis that can lead to permanent neurological damage, even death.

The current formulations of Encepur® are free of any preservative and additional protein stabilizers. A special rapid immunization schedule is approved. Protecting antibodies appear within 21 days.

Rabipur®/ RabAvert®
(PCEC rabies vaccine)
Effective pre-exposure immunization and post-exposure treatment against rabies.

Rabies is a fatal infectious disease caused when the rabies virus invades the central nervous system. Rabies is most often spread from animal to animal or animal to human through contact with infected saliva via a bite or scratch. Approximately 60,000 rabies deaths are reported globally every year and up to 50 % of all rabies victims are children.

Novartis's purified chick embryo cell rabies vaccine (trademarked as Rabipur® and RabAvert®) is the most widely used high quality cell culture vaccine with more than 55 million doses administered in ~70 countries worldwide.

Rabipur®/ RabAvert® is WHO recommended and FDA approved. A proven pre-exposure vaccination and post-exposure prophylaxis for all age groups.

Important Safety Information: The most commonly occurring adverse reactions are injection site reactions, such as injection site erythema, induration, and pain; flu-like symptoms, such as asthenia, fatigue, fever, headache, myalgia, and malaise; arthralgia, dizziness, lymphadenopathy, nausea, and rash. In very rare cases, neurological and neuroparalytical events have been reported in temporal association with administration of RabAvert®. History of anaphylaxis to the vaccine or any of the vaccine components constitutes a contraindication to pre-exposure vaccination with this vaccine. There is no contraindication to post-exposure immunization. For more information please see our prescribing information.

Arilvax®
Arilvax® vaccine for yellow fever is approved for sale in more than 10 countries, including the United Kingdom. (Globally exc. U.S.)

Typhoral® L
Oral typhoid vaccine

HAVpur®
Inactivated Hepatitis A vaccine

Dukoral™
Dukoral™ vaccine for cholera has been recommended for marketing authorization by the Committee for Proprietary Medicinal Products of the European Union. (Europe)

NOTE:
Products presented on this website are subject to national regulatory approval, licensing and advertising rules which differ from country to country.

These products may not be approved and/or licensed in all countries where this website is accessible and, with the exception of Fluvirin® and RabAvert®, have not been approved by the U.S. Food and Drug Administration.

In jurisdictions where the presentation and advertising of our products is restricted to members of the medical profession and pharmaceutical organization, such presentation and advertising as are found on this site are not intended for the public and should not be accessed by users who are not members of a medical profession or pharmaceutical organization.

These products, with the exception of Fluvirin® and RabAvert®, are not intended for use by customers, patients or health care professionals in the United States.

Members of the medical profession and pharmaceutical trade are requested not to use this website for any purpose regulated by their respective national laws such as drug approval information, license information, health product promotion or any other purpose for which this international website is not intended.